Literature DB >> 9292080

IgA-epidermolysis bullosa acquisita in a child resulting in blindness.

F Caux1, G Kirtschig, F Lemarchand-Venencie, P Y Venencie, T Hoang-Xuan, H Robin, L Dubertret, C Prost.   

Abstract

Epidermolysis bullosa acquisita (EBA) is an acquired subepidermal bullous disease characterized by IgG autoantibodies directed against type VII collagen, the major component of anchoring fibrils. The classical phenotype of EBA is a non-inflammatory, mechanobullous disease resembling the dystrophic forms of inherited epidermolysis bullosa. Mucous membrane involvement is frequent but usually mild. We report a 1-year-old girl suffering from IgA-EBA, who presented with an initial eruption of disseminated urticarial lesions and tense blisters of the skin but subsequently developed severe oral and ocular lesions reminiscent of cicatricial pemphigoid. Direct immunofluorescence of the skin and buccal mucosa revealed linear IgA and C3 at the basement membrane zone (BMZ). IgA anti-BMZ autoantibodies stained the dermal side of salt-split skin by indirect immunofluorescence and recognized a dermal protein of 290 kDa co-migrating with type VII collagen by immunoblotting. Direct and indirect immunoelectron microscopy revealed IgA deposits overlying the anchoring fibrils. The ocular involvement led to total blindness in spite of intense treatment. This case of childhood IgA-EBA is particularly striking because of the cicatricial pemphigoid phenotype with severe ocular involvement which resulted in blindness. It reinforces the necessity to use modern immunological methods to classify autoimmune bullous diseases in order to allow early and appropriate treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292080     DOI: 10.1046/j.1365-2133.1997.18191915.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

Review 1.  Bullous Diseases in Children: A Review of Clinical Features and Treatment Options.

Authors:  Brittney Schultz; Kristen Hook
Journal:  Paediatr Drugs       Date:  2019-10       Impact factor: 3.022

2.  Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.

Authors:  Ralf J Ludwig
Journal:  ISRN Dermatol       Date:  2013-07-15

Review 3.  A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.

Authors:  Brendon W H Lee; Jeremy C K Tan; Melissa Radjenovic; Minas T Coroneo; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

4.  Molecular diagnosis of anti-laminin 332 (epiligrin) mucous membrane pemphigoid.

Authors:  Roxana Chiorean; Sorina Danescu; Oana Virtic; Mayson B Mustafa; Adrian Baican; Annette Lischka; Takashi Hashimoto; Yoshinobu Kariya; Manuel Koch; Cassian Sitaru
Journal:  Orphanet J Rare Dis       Date:  2018-07-06       Impact factor: 4.123

Review 5.  Molecular diagnosis in autoimmune skin blistering conditions.

Authors:  J V Otten; T Hashimoto; M Hertl; A S Payne; C Sitaru
Journal:  Curr Mol Med       Date:  2014-01       Impact factor: 2.222

6.  Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients.

Authors:  Hiroaki Iwata; Artem Vorobyev; Hiroshi Koga; Andreas Recke; Detlef Zillikens; Catherine Prost-Squarcioni; Norito Ishii; Takashi Hashimoto; Ralf J Ludwig
Journal:  Orphanet J Rare Dis       Date:  2018-09-04       Impact factor: 4.123

Review 7.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.